117 related articles for article (PubMed ID: 22370312)
41. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
42. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute.
Hsiao HH; Liu YC; Tsai HJ; Chen LT; Lee CP; Chuan CH; Wang JY; Yang SF; Tseng YT; Lin SF
Kaohsiung J Med Sci; 2006 Dec; 22(12):599-603. PubMed ID: 17116620
[TBL] [Abstract][Full Text] [Related]
43. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
Merante S; Orlandi E; Bernasconi P; Calatroni S; Boni M; Lazzarino M
Haematologica; 2005 Jul; 90(7):979-81. PubMed ID: 15996937
[TBL] [Abstract][Full Text] [Related]
44. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
45. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Hennessy B; Giles F; Cortes J; O'brien S; Ferrajoli A; Ossa G; Garcia-Manero G; Faderl S; Kantarjian H; Verstovsek S
Am J Hematol; 2004 Nov; 77(3):209-14. PubMed ID: 15495258
[TBL] [Abstract][Full Text] [Related]
46. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
47. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
48. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
49. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
[TBL] [Abstract][Full Text] [Related]
50. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
[TBL] [Abstract][Full Text] [Related]
51. Clinical remission of Merkel cell carcinoma after treatment with imatinib.
Loader DE; Feldmann R; Baumgartner M; Breier F; Schrama D; Becker JC; Steiner A
J Am Acad Dermatol; 2013 Oct; 69(4):e181-3. PubMed ID: 24034390
[No Abstract] [Full Text] [Related]
52. Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD.
Kim H; Kim NH; Kang HJ; Lee JW; Kim MS; Park KD; Shin HY; Ahn HS
Pediatr Transplant; 2012 Dec; 16(8):910-2. PubMed ID: 23050745
[No Abstract] [Full Text] [Related]
53. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.
Brunet-Possenti F; Hermine O; Marinho E; Crickx B; Descamps V
J Am Acad Dermatol; 2013 Aug; 69(2):319-20. PubMed ID: 23866873
[No Abstract] [Full Text] [Related]
54. Dasatinib therapy for systemic mastocytosis: four cases.
Purtill D; Cooney J; Sinniah R; Carnley B; Cull G; Augustson B; Cannell P
Eur J Haematol; 2008 May; 80(5):456-8. PubMed ID: 18284618
[No Abstract] [Full Text] [Related]
55. Cutaneous lupus mucinosis successfully treated with systemic corticosteroid and systemic tacrolimus combination therapy.
Sugiura K; Tanahashi K; Muro Y; Akiyama M
J Am Acad Dermatol; 2013 Oct; 69(4):e200-2. PubMed ID: 24034403
[No Abstract] [Full Text] [Related]
56. Long term follow-up of Polycythemia Vera patients treated with imatinib mesylate.
Michael Jones C
Leuk Res; 2012 Jul; 36(7):815-6. PubMed ID: 22483066
[No Abstract] [Full Text] [Related]
57. Response of urticaria pigmentosa to cladribine in a patient with systemic mastocytosis.
Bennett M; Chubar Y
Br J Haematol; 2013 Feb; 160(4):420. PubMed ID: 23205635
[No Abstract] [Full Text] [Related]
58. Midostaurin in Advanced Systemic Mastocytosis.
Chandesris MO; Damaj G; Canioni D; Brouzes C; Lhermitte L; Hanssens K; Frenzel L; Cherquaoui Z; Durieu I; Durupt S; Gyan E; Beyne-Rauzy O; Launay D; Faure C; Hamidou M; Besnard S; Diouf M; Schiffmann A; Niault M; Jeandel PY; Ranta D; Gressin R; Chantepie S; Barete S; Dubreuil P; Bourget P; Lortholary O; Hermine O;
N Engl J Med; 2016 Jun; 374(26):2605-7. PubMed ID: 27355555
[No Abstract] [Full Text] [Related]
59. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study.
Rallidis LS; Drakoulis CK; Parasi AS
Atherosclerosis; 2004 May; 174(1):193-6. PubMed ID: 15135271
[No Abstract] [Full Text] [Related]
60. Rare lesion in the uterine cervix with irregular vaginal bleeding.
Jia QN; Fang K; Liu YH
Am J Obstet Gynecol; 2019 Jun; 220(6):598-599. PubMed ID: 30521797
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
